Zeria Pharmaceutical Co., Ltd. (TYO:4559)
2,088.00
+4.00 (0.19%)
Nov 13, 2026, 3:30 PM JST
Zeria Pharmaceutical Revenue
Zeria Pharmaceutical had revenue of 24.01B JPY in the quarter ending September 30, 2026, with 17.30% growth. This brings the company's total for the last twelve months to 94.66B, up 11.56% year-over-year. In the fiscal year ending March 31, 2026, Zeria Pharmaceutical had annual revenue of 89.16B with 2.12% growth. That makes Zeria Pharmaceutical the 10,321st largest company in the world by revenue and 1,077th in Japan.
Revenue (ttm)
94.66B
Revenue Growth
+11.56%
P/S Ratio
0.97
Revenue / Employee
54.15M
Employees
1,748
Market Cap
92.04B
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full Zeria Pharmaceutical breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 89.16B | 1.85B | 2.12% |
| Mar 31, 2025 | 87.31B | 11.59B | 15.30% |
| Mar 31, 2024 | 75.73B | 7.34B | 10.74% |
| Mar 31, 2023 | 68.38B | 8.85B | 14.87% |
| Mar 31, 2022 | 59.53B | 4.09B | 7.38% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Towa Pharmaceutical | 285.49B |
| Sawai Group Holdings | 203.79B |
| Nippon Shinyaku | 180.29B |
| Mochida Pharmaceutical | 126.33B |
| KYORIN Pharmaceutical | 125.02B |
| Kissei Pharmaceutical | 97.08B |
| Kaken Pharmaceutical | 86.47B |
| ASKA Pharmaceutical Holdings | 71.50B |